Treatment outcomes of advanced/metastatic extramammary Paget's disease in Korean patients: KCSG‐RC20‐06
Abstract Background Extramammary Paget's disease (EMPD) is rare. There are no standard treatments due to its rarity and few clinical trials. Methods The objective of this multicenter study was to investigate treatment outcomes of Korean patients with advanced/metastatic EMPD. Data were collecte...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-07-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.6190 |
| _version_ | 1797744858512752640 |
|---|---|
| author | Byeong Seok Sohn Jeongeun Kim Miso Kim Jung Yong Hong Jieun Lee Song Ee Park Hyojeong Kim Hyo Jin Lee Eun Joo Kang Soon Il Lee In Hee Lee Seok Jae Huh Jeongmin Jo Ho Young Kim |
| author_facet | Byeong Seok Sohn Jeongeun Kim Miso Kim Jung Yong Hong Jieun Lee Song Ee Park Hyojeong Kim Hyo Jin Lee Eun Joo Kang Soon Il Lee In Hee Lee Seok Jae Huh Jeongmin Jo Ho Young Kim |
| author_sort | Byeong Seok Sohn |
| collection | DOAJ |
| description | Abstract Background Extramammary Paget's disease (EMPD) is rare. There are no standard treatments due to its rarity and few clinical trials. Methods The objective of this multicenter study was to investigate treatment outcomes of Korean patients with advanced/metastatic EMPD. Data were collected retrospectively from 14 institutions participating in Korean Cancer Study Group (KCSG) Rare Cancer Committee. Results A total of 37 patients were identified. Of these 37 patients, 6 received locoregional therapy as a first‐line treatment. In 31 patients who received systemic chemotherapy as a first‐line treatment, platinum‐based chemotherapy (n = 22) achieved an objective response rate (ORR) of 45.5% and a median progression‐free survival (PFS) of 7.89 months. Taxane‐based chemotherapy (n = 8) achieved an objective response rate of 62.5% and median PFS of 9.73 months. In second‐line chemotherapy, platinum‐based chemotherapy (n = 4) had a disease control rate (DCR) of 75.0% and median PFS of 3.45 months. Taxane‐based chemotherapy (n = 8) had a DCR of 75.0% and a median PFS of 8.67 months. Six patients received anti‐human epidermal growth factor receptor 2 (HER2) antibody during first‐ and second‐line chemotherapy. Overall, systemic chemotherapy combined with anti‐HER2 antibody had an ORR of 100% and a median PFS of 13.31 months. The ORR and PFS with systemic chemotherapy combined with trastuzumab was better than platinum‐ and taxane‐based chemotherapy only. Conclusions Due to its rarity, advanced or metastatic EMPD still has no established standard treatment. Results of our study indicate that the combination of trastuzumab with taxane has longer survival than trastuzumab monotherapy or conventional platinum‐ or taxane‐based chemotherapy. |
| first_indexed | 2024-03-12T15:15:27Z |
| format | Article |
| id | doaj.art-df826c92a4414bae9cbf04d45015e3ab |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-03-12T15:15:27Z |
| publishDate | 2023-07-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-df826c92a4414bae9cbf04d45015e3ab2023-08-11T14:51:17ZengWileyCancer Medicine2045-76342023-07-011214151591517510.1002/cam4.6190Treatment outcomes of advanced/metastatic extramammary Paget's disease in Korean patients: KCSG‐RC20‐06Byeong Seok Sohn0Jeongeun Kim1Miso Kim2Jung Yong Hong3Jieun Lee4Song Ee Park5Hyojeong Kim6Hyo Jin Lee7Eun Joo Kang8Soon Il Lee9In Hee Lee10Seok Jae Huh11Jeongmin Jo12Ho Young Kim13Department of Internal Medicine, Sanggye Paik Hospital Inje University College of Medicine Seoul South KoreaDepartment of Oncology, Asan Medical Center University of Ulsan College of Medicine Seoul South KoreaDepartment of Internal Medicine Seoul National University College of Medicine and Seoul National University Hospital Seoul South KoreaDivision of Hematology‐Oncology, Department of Medicine Samsung Medical Center, Sungkyunkwan University School of Medicine Seoul South KoreaDivision of Medical Oncology, Department of Internal Medicine Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea Seoul South KoreaDivision of Hematology‐Oncology, Department of Medicine Chung‐Ang University College of Medicine Seoul South KoreaDivision of Hemato‐Oncology, Department of Internal Medicine Pusan National University School of Medicine Busan South KoreaDivision of Hematology/Oncology, Department of Internal Medicine College of Medicine, Chungnam National University Daejeon South KoreaDivision of Hematology‐Oncology, Department of Internal Medicine Korea University Guro Hospital, Korea University College of Medicine Seoul South KoreaDivision of Hematology‐Oncology, Department of Internal Medicine Dankook University College of Medicine Cheonan South KoreaDepartment of Oncology/Hematology Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University Daegu South KoreaDepartment of Internal Medicine Dong‐A University College of Medicine Busan South KoreaDepartment of Hematology‐Oncology Ewha Womans University Medical Center Seoul South KoreaDepartment of Hematological Oncology Hallym University Sacred Heart Hospital, Hallym University College of Medicine Anyang‐si South KoreaAbstract Background Extramammary Paget's disease (EMPD) is rare. There are no standard treatments due to its rarity and few clinical trials. Methods The objective of this multicenter study was to investigate treatment outcomes of Korean patients with advanced/metastatic EMPD. Data were collected retrospectively from 14 institutions participating in Korean Cancer Study Group (KCSG) Rare Cancer Committee. Results A total of 37 patients were identified. Of these 37 patients, 6 received locoregional therapy as a first‐line treatment. In 31 patients who received systemic chemotherapy as a first‐line treatment, platinum‐based chemotherapy (n = 22) achieved an objective response rate (ORR) of 45.5% and a median progression‐free survival (PFS) of 7.89 months. Taxane‐based chemotherapy (n = 8) achieved an objective response rate of 62.5% and median PFS of 9.73 months. In second‐line chemotherapy, platinum‐based chemotherapy (n = 4) had a disease control rate (DCR) of 75.0% and median PFS of 3.45 months. Taxane‐based chemotherapy (n = 8) had a DCR of 75.0% and a median PFS of 8.67 months. Six patients received anti‐human epidermal growth factor receptor 2 (HER2) antibody during first‐ and second‐line chemotherapy. Overall, systemic chemotherapy combined with anti‐HER2 antibody had an ORR of 100% and a median PFS of 13.31 months. The ORR and PFS with systemic chemotherapy combined with trastuzumab was better than platinum‐ and taxane‐based chemotherapy only. Conclusions Due to its rarity, advanced or metastatic EMPD still has no established standard treatment. Results of our study indicate that the combination of trastuzumab with taxane has longer survival than trastuzumab monotherapy or conventional platinum‐ or taxane‐based chemotherapy.https://doi.org/10.1002/cam4.6190chemotherapymetastatic extramammary Paget's diseaseoverall survivalprogression‐free survivaltrastuzumab |
| spellingShingle | Byeong Seok Sohn Jeongeun Kim Miso Kim Jung Yong Hong Jieun Lee Song Ee Park Hyojeong Kim Hyo Jin Lee Eun Joo Kang Soon Il Lee In Hee Lee Seok Jae Huh Jeongmin Jo Ho Young Kim Treatment outcomes of advanced/metastatic extramammary Paget's disease in Korean patients: KCSG‐RC20‐06 Cancer Medicine chemotherapy metastatic extramammary Paget's disease overall survival progression‐free survival trastuzumab |
| title | Treatment outcomes of advanced/metastatic extramammary Paget's disease in Korean patients: KCSG‐RC20‐06 |
| title_full | Treatment outcomes of advanced/metastatic extramammary Paget's disease in Korean patients: KCSG‐RC20‐06 |
| title_fullStr | Treatment outcomes of advanced/metastatic extramammary Paget's disease in Korean patients: KCSG‐RC20‐06 |
| title_full_unstemmed | Treatment outcomes of advanced/metastatic extramammary Paget's disease in Korean patients: KCSG‐RC20‐06 |
| title_short | Treatment outcomes of advanced/metastatic extramammary Paget's disease in Korean patients: KCSG‐RC20‐06 |
| title_sort | treatment outcomes of advanced metastatic extramammary paget s disease in korean patients kcsg rc20 06 |
| topic | chemotherapy metastatic extramammary Paget's disease overall survival progression‐free survival trastuzumab |
| url | https://doi.org/10.1002/cam4.6190 |
| work_keys_str_mv | AT byeongseoksohn treatmentoutcomesofadvancedmetastaticextramammarypagetsdiseaseinkoreanpatientskcsgrc2006 AT jeongeunkim treatmentoutcomesofadvancedmetastaticextramammarypagetsdiseaseinkoreanpatientskcsgrc2006 AT misokim treatmentoutcomesofadvancedmetastaticextramammarypagetsdiseaseinkoreanpatientskcsgrc2006 AT jungyonghong treatmentoutcomesofadvancedmetastaticextramammarypagetsdiseaseinkoreanpatientskcsgrc2006 AT jieunlee treatmentoutcomesofadvancedmetastaticextramammarypagetsdiseaseinkoreanpatientskcsgrc2006 AT songeepark treatmentoutcomesofadvancedmetastaticextramammarypagetsdiseaseinkoreanpatientskcsgrc2006 AT hyojeongkim treatmentoutcomesofadvancedmetastaticextramammarypagetsdiseaseinkoreanpatientskcsgrc2006 AT hyojinlee treatmentoutcomesofadvancedmetastaticextramammarypagetsdiseaseinkoreanpatientskcsgrc2006 AT eunjookang treatmentoutcomesofadvancedmetastaticextramammarypagetsdiseaseinkoreanpatientskcsgrc2006 AT soonillee treatmentoutcomesofadvancedmetastaticextramammarypagetsdiseaseinkoreanpatientskcsgrc2006 AT inheelee treatmentoutcomesofadvancedmetastaticextramammarypagetsdiseaseinkoreanpatientskcsgrc2006 AT seokjaehuh treatmentoutcomesofadvancedmetastaticextramammarypagetsdiseaseinkoreanpatientskcsgrc2006 AT jeongminjo treatmentoutcomesofadvancedmetastaticextramammarypagetsdiseaseinkoreanpatientskcsgrc2006 AT hoyoungkim treatmentoutcomesofadvancedmetastaticextramammarypagetsdiseaseinkoreanpatientskcsgrc2006 |